Quarterly Activities Report and Appendix 4C Cash Flow Report
Filed with ASX · · 10 pages · English
Summary by 6ix AI
The report highlights the company's appointment as a supplier under a NSW Health public hospital supply contract and positive results from its second independent AI validation program. Additionally, AlgoraeRx has expanded its product portfolio and secured funding for further validation of its drug combinations. The financial overview indicates a cash position at the end of the quarter and outlines operational expenditures.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
• NSW Health supply contract: Following a competitive tender, AlgoraeRx was appointed one of several suppliers under a NSW Health public hospital supply contract, for an initial term of three years with two optional one-year extensions (3+1+1 years). First supply under purchase orders is expected in the December 2026 quarter. • Commercial and regulatory execution: AlgoraeRx advanced its commercial
Algorae Pharmaceuticals Limited on 6ix
Earlier from Algorae Pharmaceuticals
- Updated Securities Trading Policy
- Algorae executes Licence & Supply Agreement with Umedica
- Peter Mac partners with Algorae on 3rd AI validation program
- Notice of Annual General Meeting/Proxy Form
- Change of Director's Interest Notice - DH
Later from Algorae Pharmaceuticals
All Algorae Pharmaceuticals news releasesFollow Algorae Pharmaceuticals into a list and get an email when it puts out news.
Follow Algorae Pharmaceuticals